LONDON Oct 4 AstraZeneca said on
Tuesday its heart drug Brilinta failed to show any benefit over
an existing medicine in treating peripheral artery disease (PAD)
in a large-scale clinical trial.
The company said it was disappointed that the drug, which is
used to treat heart attack patients, had not been successful for
"We are disappointed that the EUCLID trial results showed
Brilinta did not demonstrate a benefit over clopidogrel in this
specific symptomatic PAD population," said Sean Bohen, Executive
Vice President, Global Medicines Development and Chief Medical
Officer at AstraZeneca.
(Reporting by Paul Sandle; editing by Kate Holton)